Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
13.63
+4.07 (42.57%)
At close: May 15, 2026, 4:00 PM EDT
13.90
+0.27 (1.98%)
Pre-market: May 18, 2026, 6:41 AM EDT
Ernexa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
15.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 582.00K | 514.00K | 755.88% |
| Dec 31, 2023 | 68.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 24.06M | 194.00K | 0.81% |
| Dec 31, 2011 | 23.87M | -1.44M | -5.69% |
| Dec 31, 2010 | 25.31M | -505.00K | -1.96% |
| Dec 31, 2009 | 25.81M | -1.68M | -6.12% |
| Dec 31, 2008 | 27.50M | -3.05M | -9.97% |
| Dec 31, 2007 | 30.54M | -2.44M | -7.41% |
| Dec 31, 2006 | 32.99M | 2.24M | 7.27% |
| Dec 31, 2005 | 30.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lipocine | 2.00M |
| SeaStar Medical Holding | 1.44M |
| CytoMed Therapeutics | 669.28K |
| Exicure | 500.00K |
| Lexaria Bioscience | 368.00K |
| Cocrystal Pharma | 225.00K |
ERNA News
- 6 days ago - Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - GlobeNewsWire
- 10 days ago - Ernexa Therapeutics initiated with a Buy at Brookline - TheFly
- 10 days ago - 3 Penny Stocks to Watch Now, 5/7/26 - TipRanks
- 11 days ago - Ernexa Therapeutics announces new ERNA-101 preclinical data - TheFly
- 11 days ago - Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models - GlobeNewsWire
- 17 days ago - Ernexa Therapeutics announces 1-for-25 reverse stock split - TheFly
- 17 days ago - Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split - GlobeNewsWire
- 6 weeks ago - Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 - GlobeNewsWire